Remimazolam besylate is under clinical development by PAION and currently in Phase I for Substance (Drug) Abuse. According to GlobalData, Phase I drugs for Substance (Drug) Abuse have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Remimazolam besylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Remimazolam besylate overview

Remimazolam (Anerem, Byfavo, Ruima) is a benzodiazepine derivative, acts as a sedating agent. It is formulated as powder for solution for intravenous route of administration. Remimazolam is indicated for the management of  general anesthesia and procedural sedation in adults undergoing procedures lasting 30 mins or less.

Remimazolam (CNS-7056/ONO-2745) is under development for drug abuse, and for procedural, conscious and ICU sedation in short procedures. It is administered by intravenous and intranasal routes. It is a water-soluble benzodiazepine derivative. The drug candidate is a GABA-A receptor modulator. It was also under development for sedation in Japan.

PAION overview

PAION operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs used for out-patient and hospital-based sedation, anesthesia and critical care services. The company’s lead product, remimazolam, is designed for the treatment of patients requiring sedation. PAION currently develops remimazolam for general anesthesia. The company completed clinical development program for general anesthesia in Japan and initiated a Phase three trial in the European Union. It has presence in the UK, the US and Germany. PAION is headquartered in Aachen, Germany

For a complete picture of Remimazolam besylate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.